-
2025-522656-68-00
6
2025-10-15
Metastatic breast cancers
-
2023-510558-18-00
4
2025-10-13
locally advanced head and neck squamous cell carcinoma
-
2025-521147-21-00
4
2025-10-08
Lung Cancer
-
2024-511989-36-00
5
2025-09-24
Ewing Sarcoma
-
2024-520386-31-00
5
2025-09-22
Locally Advanced Head & Neck Squamous Cell Carcinoma
-
2025-520740-16-00
5
2025-09-19
Primary Aldosteronism defined by excess aldosterone secretion
-
2024-517525-10-00
4
2025-09-15
APOL1 Kidney Disease (AKD)
-
2025-521660-35-00
5
2025-09-11
Hereditary Angioedema
-
2025-520519-14-00
5
2025-09-03
Atherosclerotic Cardiovascular Disease
-
2024-514273-22-00
9
2025-09-02
Esophageal squamous cell carcinoma
-
2024-514030-20-00
4
2025-08-29
colorectal cancer
-
2024-516772-15-00
1
2025-08-29
Prostate Cancer
-
2024-517167-23-00
5
2025-08-28
Chronic Hepatitis D Infection
-
2024-518154-16-00
5
2025-08-27
non-small cell lung cancer
-
2024-515875-36-00
4
2025-08-18
Advanced biliary tract cancer (BTC)
-
2023-507071-21-01
1
2025-08-14
Relapsed/Refractory Multiple Myeloma
-
2024-516036-94-00
9
2025-08-12
Metastatic castrate resistant prostate cancer - mCRPC
-
2024-515561-34-01
6
2025-08-04
Acute ischemic stroke with recent ingestion of direct oral anticoagula
-
2022-502983-19-00
4
2025-07-31
High-Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cance
-
2024-513589-20-00
9
2025-07-29
Treatment-resistant generalized Myasthenia Gravis
-
2024-511667-28-00
1
2025-07-21
Plasma cell myeloma refractory
-
2024-516162-11-00
5
2025-07-14
Endocrine-Sensitive phosphatidylinositol 3-kinase (PIK3CA)-Mutated, Ho
-
2024-512981-33-00
4
2025-07-09
Metastatic Colorectal Cancer
-
2024-513682-40-01
5
2025-07-04
Non-squamous (NSQ), Stage IV or Recurrent Non-small Cell Lung Cancer